+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Specific COX-2 Inhibitors Market - Global Forecast 2026-2032- Product Image
Specific COX-2 Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Specific COX-2 Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6150960
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Specific COX-2 Inhibitors Market is projected to reach USD 3.32 Billion in 2026. It is expected to continue growing at a CAGR of 5.95%, reaching USD 4.70 Billion by 2032.

Specific COX-2 Inhibitors: Executive Summary and Strategic Context

Specific COX-2 inhibitors are prescription medicines designed to selectively inhibit cyclooxygenase-2, an enzyme associated with prostaglandin production, pain, and inflammation. Their clinical relevance is linked to the management of conditions such as osteoarthritis, rheumatoid arthritis, and acute pain, while their use requires attention to cardiovascular, gastrointestinal, renal, and hepatic considerations. Market development is shaped by prescribing guidance, safety monitoring, generic competition, regulatory decisions, and changing patterns of chronic disease and pain management.

Safety-Led Innovation Is Reshaping the COX-2 Inhibitor Landscape

The landscape is shifting from simple emphasis on anti-inflammatory efficacy toward individualized benefit-risk assessment. Clinicians increasingly consider cardiovascular history, gastrointestinal vulnerability, kidney function, age, concomitant medicines, treatment duration, and dose when selecting therapy. Evidence-based prescribing, post-market safety surveillance, label changes, and efforts to use the lowest effective dose for the shortest appropriate duration remain central to responsible adoption.

Additional transformation is coming from multimodal pain care, expanded use of nonpharmacological interventions, improved diagnostic pathways, and broader attention to medication stewardship. These trends favor products and care pathways that demonstrate clinically meaningful utility while supporting adherence, monitoring, and appropriate patient selection.

Artificial Intelligence Is Strengthening Evidence, Safety, and Patient Selection

Artificial intelligence can support the COX-2 inhibitor ecosystem by identifying safety signals in clinical and real-world data, improving patient-risk stratification, and helping clinicians reconcile medicines that may increase cardiovascular, renal, or gastrointestinal risk. Natural-language tools can also structure information from medical records, adverse-event reports, and published evidence, potentially improving the speed and consistency of pharmacovigilance.

However, AI does not replace clinical judgment or prospective validation. Bias in training data, incomplete records, privacy requirements, explainability, and regulatory accountability remain material constraints. Responsible implementation therefore requires validated models, human oversight, transparent performance assessment, and governance aligned with medicine-safety standards.

Regional Insights: Access and Safety Priorities Vary Across Six Geographies

North America combines sophisticated regulatory oversight, extensive clinical data infrastructure, and strong emphasis on cardiovascular and gastrointestinal risk management. Latin America is characterized by heterogeneous reimbursement, regulatory, and healthcare access conditions, making affordability, supply continuity, and prescribing education important considerations. Europe places substantial weight on comparative safety, pharmacovigilance, health-technology assessment, and coordinated regulatory standards.

The Middle East shows variation in healthcare-system maturity and procurement structures, with specialist-led care and medicine availability influencing use. Africa faces uneven access to diagnosis, specialist services, pharmacovigilance capacity, and reliable pharmaceutical supply, increasing the importance of essential-medicine governance and clinician training. Asia-Pacific presents considerable diversity: advanced systems emphasize evidence, safety, and aging-related disease management, while emerging systems continue to address affordability, quality assurance, and access to appropriate diagnosis and follow-up.

Group Insights: Policy Alignment and Procurement Shape Adoption

ASEAN markets differ in regulatory maturity, reimbursement, and supply-chain capacity, so regional cooperation and harmonized quality standards can help improve access while preserving safety oversight. BRICS members bring varied disease burdens, domestic manufacturing capabilities, and health-policy priorities; collaboration on quality, evidence generation, and pharmacovigilance may support more resilient availability. The European Union benefits from coordinated regulatory structures, although national reimbursement and clinical-practice differences continue to influence use.

G7 health systems generally emphasize robust evidence, safety monitoring, and value-based prescribing. GCC countries often combine strong healthcare investment with centralized or semi-centralized procurement and a high reliance on imported medicines. NATO members span diverse health systems, but shared preparedness and medicine-security priorities can reinforce attention to supply continuity, regulatory cooperation, and responsible pharmaceutical stewardship.

Country Insights: Diverse Regulatory and Care Environments Require Local Strategy

Australia and Canada emphasize regulated access, evidence-based prescribing, and safety monitoring across geographically dispersed populations. Brazil and Mexico must balance access, affordability, regulatory oversight, and uneven healthcare capacity. China and India combine large patient populations with expanding domestic pharmaceutical capabilities, while regulatory modernization, quality consistency, and appropriate prescribing remain important. Japan and South Korea have advanced healthcare infrastructures and aging populations, supporting demand for carefully monitored pain and inflammatory-disease management.

France, Germany, Italy, Spain, and the United Kingdom operate within mature European evidence and safety frameworks, with national reimbursement, procurement, and prescribing policies shaping practical access. Russia’s environment is influenced by domestic supply considerations, regulatory conditions, and healthcare-system priorities. The United States has extensive clinical data and regulatory scrutiny, with utilization strongly affected by safety communication, payer policy, generic availability, and clinician assessment of individual risk.

Strategic Priorities for Leaders in Specific COX-2 Inhibitors

Industry leaders should prioritize rigorous benefit-risk evidence, clear patient-selection guidance, and continuous pharmacovigilance rather than relying solely on efficacy positioning. Evidence programs should address cardiovascular, renal, gastrointestinal, and hepatic outcomes, relevant comorbidities, treatment duration, and use alongside common concomitant medicines. Clear labeling and practical tools can help clinicians and patients understand contraindications, warning signs, and monitoring needs.

Operationally, leaders should strengthen supply resilience, maintain consistent product quality, and tailor access strategies to local reimbursement and procurement conditions. Digital and AI-enabled tools should be deployed only with clinical validation, privacy safeguards, bias testing, and human oversight. Partnerships with healthcare providers and public-health stakeholders can support adherence, appropriate duration of therapy, adverse-event reporting, and education on nonpharmacological pain management.

Research Methodology: Evidence-Based Synthesis of the COX-2 Inhibitor Environment

This executive summary uses a structured qualitative synthesis of established clinical, regulatory, pharmacovigilance, healthcare-policy, and pharmaceutical-access considerations relevant to specific COX-2 inhibitors. The assessment organizes findings across therapeutic safety, innovation, artificial intelligence, regional systems, economic groupings, and country-level healthcare environments.

Interpretation emphasizes verifiable clinical and policy themes rather than numerical market measures. Regional and country comparisons are framed around documented differences in regulation, reimbursement, healthcare infrastructure, disease-management priorities, procurement, and medicine-safety capabilities. Conclusions should be refreshed as treatment guidelines, regulatory communications, safety evidence, reimbursement policies, and supply conditions change.

Conclusion: Responsible, Risk-Aware Use Will Define Long-Term Relevance

Specific COX-2 inhibitors remain clinically relevant where selective anti-inflammatory treatment is appropriate, but their role is inseparable from careful patient selection and safety management. The most durable opportunities will come from evidence that clarifies benefit-risk profiles, supports individualized treatment decisions, and integrates medication with broader pain and inflammatory-disease care.

Across regions, groups, and countries, successful strategies will depend on regulatory alignment, reliable access, quality assurance, pharmacovigilance, and clinician education. Artificial intelligence can improve these functions when deployed transparently and responsibly, but it should complement-not replace-clinical expertise and established medicine-safety governance.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Specific COX-2 Inhibitors Market, by Drug Type
7.1. Introduction
7.2. Celecoxib
7.3. Etoricoxib
7.4. Lumiracoxib
7.5. Rofecoxib
7.6. Valdecoxib
8. Specific COX-2 Inhibitors Market, by Dosage Form
8.1. Introduction
8.2. Capsules
8.3. Injectables
8.4. Oral Suspensions
8.5. Tablets
9. Specific COX-2 Inhibitors Market, by Indication
9.1. Introduction
9.2. Acute Pain
9.3. Ankylosing Spondylitis
9.4. Dysmenorrhea
9.5. Osteoarthritis
9.6. Rheumatoid Arthritis
10. Specific COX-2 Inhibitors Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Specific COX-2 Inhibitors Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Specific COX-2 Inhibitors Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Specific COX-2 Inhibitors Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Specific COX-2 Inhibitors Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bayer AG
16.2. Dr. Reddy's Laboratories Ltd.
16.3. Lupin Limited
16.4. Merck & Co., Inc.
16.5. Novartis International AG
16.6. Pfizer Inc.
16.7. Sandoz International GmbH
16.8. Sun Pharmaceutical Industries Ltd.
16.9. Teva Pharmaceutical Industries Ltd.
16.10. Torrent Pharmaceuticals Ltd.
16.11. Viatris Inc.
16.12. Zydus Lifesciences Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Specific COX-2 Inhibitors Market, Years Considered for the Study
FIGURE 2. Global Specific COX-2 Inhibitors Market, Research Design
FIGURE 3. Global Specific COX-2 Inhibitors Market, Research Framework
FIGURE 4. Global Specific COX-2 Inhibitors Market, Data Triangulation
FIGURE 5. Global Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Specific COX-2 Inhibitors Market Size, by Drug Type, 2025 vs 2032 (%)
FIGURE 7. Global Specific COX-2 Inhibitors Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Specific COX-2 Inhibitors Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Specific COX-2 Inhibitors Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Specific COX-2 Inhibitors Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Specific COX-2 Inhibitors Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Specific COX-2 Inhibitors Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Specific COX-2 Inhibitors Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Specific COX-2 Inhibitors Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Specific COX-2 Inhibitors Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Specific COX-2 Inhibitors Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Specific COX-2 Inhibitors Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Specific COX-2 Inhibitors Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Specific COX-2 Inhibitors Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Specific COX-2 Inhibitors Market Segmentation & Coverage
TABLE 2. Global Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 3. Global Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 4. Global Celecoxib Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Celecoxib Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Celecoxib Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Etoricoxib Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Etoricoxib Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Etoricoxib Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lumiracoxib Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lumiracoxib Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lumiracoxib Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Rofecoxib Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Rofecoxib Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Rofecoxib Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Valdecoxib Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Valdecoxib Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Valdecoxib Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 20. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Injectables Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Injectables Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Oral Suspensions Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Oral Suspensions Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Oral Suspensions Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 33. Global Acute Pain Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Acute Pain Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Acute Pain Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Ankylosing Spondylitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Ankylosing Spondylitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Ankylosing Spondylitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Dysmenorrhea Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Dysmenorrhea Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Dysmenorrhea Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Osteoarthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Osteoarthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Osteoarthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 49. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. North America Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. North America Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 77. North America Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 78. North America Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 79. North America Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. North America Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 83. Latin America Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 84. Latin America Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Latin America Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Latin America Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Europe Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Europe Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 89. Europe Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 90. Europe Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Europe Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. Europe Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Middle East Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Middle East Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 95. Middle East Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 96. Middle East Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. Middle East Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Middle East Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Africa Specific COX-2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Africa Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 101. Africa Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 102. Africa Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Africa Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Africa Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Global Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 108. ASEAN Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 109. ASEAN Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. ASEAN Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. ASEAN Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. GCC Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. GCC Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 114. GCC Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 115. GCC Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. GCC Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. GCC Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. European Union Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 120. European Union Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 121. European Union Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. European Union Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. European Union Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. BRICS Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. BRICS Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 126. BRICS Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 127. BRICS Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. BRICS Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. BRICS Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. G7 Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. G7 Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 132. G7 Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 133. G7 Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. G7 Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. G7 Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. NATO Specific COX-2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. NATO Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 138. NATO Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 139. NATO Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. NATO Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. NATO Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Global Specific COX-2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. United States Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 144. United States Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 145. United States Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 146. United States Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. United States Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. United States Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. Canada Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 150. Canada Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 151. Canada Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 152. Canada Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. Canada Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Canada Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Mexico Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 156. Mexico Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 157. Mexico Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 158. Mexico Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. Mexico Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Mexico Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Brazil Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 163. Brazil Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 164. Brazil Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. Brazil Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Brazil Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. United Kingdom Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 168. United Kingdom Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 169. United Kingdom Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 170. United Kingdom Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. United Kingdom Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. United Kingdom Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Germany Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 174. Germany Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 175. Germany Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 176. Germany Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. Germany Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Germany Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. France Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 180. France Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 181. France Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 182. France Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 183. France Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. France Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Russia Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 186. Russia Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 187. Russia Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 188. Russia Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. Russia Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Russia Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Italy Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 192. Italy Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 193. Italy Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 194. Italy Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. Italy Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Italy Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Spain Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 198. Spain Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 199. Spain Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. Spain Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. Spain Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Spain Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. China Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 204. China Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 205. China Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 206. China Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. China Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. China Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. India Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 210. India Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 211. India Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 212. India Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. India Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. India Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Japan Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 216. Japan Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 217. Japan Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 218. Japan Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. Japan Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Japan Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Australia Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 222. Australia Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 223. Australia Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 224. Australia Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. Australia Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Australia Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. South Korea Specific COX-2 Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 228. South Korea Specific COX-2 Inhibitors Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 229. South Korea Specific COX-2 Inhibitors Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 230. South Korea Specific COX-2 Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. South Korea Specific COX-2 Inhibitors Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. South Korea Specific COX-2 Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Global Specific COX-2 Inhibitors Market Share, by Key Player, 2025
TABLE 234. Global Specific COX-2 Inhibitors Market, Key Experts

Companies Mentioned

  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Related Topics

Related Reports

Chronic Pain Therapy Solutions for Joints Market - Global Forecast 2026-2032 - Product Image

Chronic Pain Therapy Solutions for Joints Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032 - Product Image

Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Cox-2 Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Cox-2 Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Post Operative Pain Management - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Post Operative Pain Management - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.